Clinical trial
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
NCT00006379 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006379 |
|---|---|
| Title | Non-Ablative Allo HSCT For Hematologic Malignancies or SAA |
| Official title | Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition, Small Intestine Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation |
| Enrollment | 58 |
| Start date | Jun 1, 2000 |
| Primary completion | Jan 1, 2004 |
| Completion | Oct 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 8, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: